Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 433

Results For "IMI"

5330 News Found

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron
News | June 27, 2022

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron

Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine


Pharma industry warming up towards adoption of digital technologies
Digitisation | June 27, 2022

Pharma industry warming up towards adoption of digital technologies

By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities


Dr. Reddy's Laboratories acquires injectable product portfolio from Eton Pharma
News | June 27, 2022

Dr. Reddy's Laboratories acquires injectable product portfolio from Eton Pharma

Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.


Novartis commits US$ 250 million to the fight against NTDs and malaria
Public Health | June 24, 2022

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.


Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer
Drug Approval | June 24, 2022

Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer

Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally


Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
News | June 24, 2022

Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine

An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.


Rivaroxaban approved in Japan for patients with PAD after revascularisation
Drug Approval | June 24, 2022

Rivaroxaban approved in Japan for patients with PAD after revascularisation

It´s the first trial to demonstrate the benefits of dual pathway inhibition


Merck KGaA doubles HPAPI production capacity in Wisconsin
News | June 24, 2022

Merck KGaA doubles HPAPI production capacity in Wisconsin

This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area


Avni announces subscription model menstrual hygiene products
Healthcare | June 23, 2022

Avni announces subscription model menstrual hygiene products

The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users


Piramal Pharma Solutions appoints Herve Berdou as COO
People | June 23, 2022

Piramal Pharma Solutions appoints Herve Berdou as COO

Brings 25 years of global operations and supply chain experience to Piramal